biuro@scopefluidics.com +48 22 376 21 14

<img src="https://scopefluidics.com/wp-content/uploads/scope-logo.svg" alt="scope-logo" width="285" height="85" title="scope-logo" />

About
Team
Our offer
Knowledge base
News
Investor relations
Contact

biuro@scopefluidics.com +48 22 376 21 14

<img src="https://scopefluidics.com/wp-content/uploads/scope-logo.svg" alt="scope-logo" width="285" height="85" title="scope-logo" />

About
Team
Our offer
Knowledge base
News
Investor relations
Contact

biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 18/2018 | 12-12-2018 | Zakończenie prewalidacji systemu PCR|ONE w laboratoriach firmy ALAB

Previous PostRAPORT ESPI 17/2018 | 29-11-2018 | Zakończenie pierwszych testów systemu Bacteromic w Narodowym Instytucie LekówNext PostRAPORT EBI 1/2019 | Rejestracja podwyższenia kapitału zakładowego Spółki

0Shares

Related Posts

PHASE Conference in Warsaw

U.S. Ambassador Mark Brzezinski Visits Scope Fluidics

Scope Fluidics team at AACC&DxPx Conference 2023

Contact Us

Tel. +48 22 376 21 14
E-mail: biuro@scopefluidics.com

Adress

Ogrodowa 58 Street
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

The company is registered in the District Court for the capital city of Warsaw in Warsaw, 13th Commercial Division of the National Court Register.

Share capital: 272 593,00 zł,

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Scope Fluidics 2022 ® All rights reserved